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237 - Poster Session
Did surgical delay due to COVD-19 affect the short- and longerterm mental health of patients?
Michelle Soloff, MD1, Trey Keel, BA, MD Candidate 20232, Aaron
Nizam, MD1, Kristy Ramphal2, Bethany Bustamante, MD1, Gary
Goldberg, MD1, Antoinette Sakaris, MD1, Michael Diefenbach, PhD1,
Danielle DePeralta, MD1, Marina Frimer, MD1
1
Northwell Health, Zucker School of Medicine at Hofstra/Northwell,
Brooklyn, NY, United States, 2Zucker School of Medicine at Hofstra/
Northwell, Hempstead, NY, United States

Objectives: At the height of the COVID-19 pandemic, the US Surgeon
General ordered the cessation of all elective surgical procedures.
We evaluated the mental health impact of COVID-19 related surgical delay on patients awaiting procedures for benign, pre-malignant
and malignant conditions. We sought to understand the short term
impact of surgical delay and to identify potential longer term mental
health affects after completion of the delayed procedure.
Methods: All patients over age 18 awaiting surgery for benign,
pre-malignant or malignant conditions in the gynecologic oncology, surgical oncology and colorectal services at Northwell Health
were eligible. Upon enrollment, participants completed a baseline
survey consisting of the Generalized Anxiety Disorder Questionnaire
(GAD-7), the Penn State Worry Questionnaire (PSWQ), and BriefIllness Patient Questionnaire (B-IPQ). Six weeks after their surgery,
participants were sent a second survey consisting of the Center for
Epidemiologic Studies Depression (CES-D) scale in addition to the
GAD-7, PSWQ, and B-IPQ.
Results: 56 patients underwent their procedure and completed the
follow-up survey. Patients with suspected benign conditions had
a longer delay in scheduling their surgery than patients with suspected/confirmed cancer or pre-malignant conditions (101.4d vs
66.3d, p<0.05). There was no correlation of length of delay with postoperative worry, anxiety, or depression scores. There was no decrease
in level of worry, as delineated by the PSWQ, among gynecologic
oncology patients when comparing pre-operative to post-operative
data. However, surgical oncology and colorectal patients demonstrated decreased post-operative worry. There was no difference in
anxiety by surgical specialty.While the surgical delay was ongoing
79% of patients considered it to be moderately to extremely concerning, with 46% indicating the highest possible level of concern. Postoperatively, 47% of the respondents indicated moderate to extreme
concern about the surgical delay, while 37% were not concerned.
Initially, the surgical delay was considered to have a moderate to
severe impact upon daily life by 65% of patients; which decreased to
53% at the time of post-operative follow-up. Interestingly, these relative decreases in patient concern were not significant when comparing pre-operative to post-operative values as a whole, by diagnosis
or by specialty. 20% of participants qualified as depressed based on
their response to the CES-D. Of these patients, 70% had a post-operatively confirmed cancer or pre-cancer. The incidence of depression
was not affected by the post-operative diagnosis.
Conclusions: Many patients experienced distress surrounding surgical delay due to the COVID-19 pandemic. This extended to their postoperative period. Gynecologic oncology patients did not experience
decreased post-operative worry, while surgical oncology and colorectal patients did. There was no significant difference in the incidence
of post-operative depression by specialty or post-operative diagnosis.

238 - Poster Session
Differences in tumor sequencing across ethnic groups in the
treatment of endometrial cancer
Austin Johnson, MD1, Gabrielle Hawkins, MD, MS1, Ana Kouri, MD1,
Leslie Clark, MD1
1
University of North Carolina at Chapel Hill, Durham, NC, United States

Objectives: We aimed to identify ethnic differences in genetic mutations associated endometrial cancer (EC), as well as differences in the
utilization of sequencing results to direct disease treatment based on
actionable mutations among different ethnic groups.
Methods: Patients of interest were identified using the EMERSE
program. Inclusion criteria included patients with endometrial
cancer who underwent solid tumor genomic sequencing between
the dates of April 2014 and January 2019 at our institution. Patients
meeting the inclusion criteria with verifiable tumor sequencing
results were included in our retrospective cohort. Patients were
excluded if they had synchronous cancers and germline or non-solid
tumor testing only. Clinical information was abstracted from the
medical record. Differences between groups were calculated using
descriptive statistics.
Results: 287 patients met inclusion criteria. The majority of patients
who underwent genomic sequencing of their tumors were non-Hispanic Caucasian (n=212, 73.9%), followed by non-Hispanic African
American (n=55, 19.2%) and Hispanic (n=6, 2.1%), a distribution that
accurately reflects the ethnic makeup of our state population. Among
patients who underwent tumor sequencing, non-Hispanic Caucasian
patients had an 82% likelihood (n=174) of having an actionable mutation, whereas non-Hispanic African American patients had a 60%
likelihood (n=33) (p<0.001). PTEN (n=107, 80.5%, p<0.001) and FGFR2
(n=28, 95.8%, p=0.04) mutations were found at a higher rate in nonHispanic Caucasian patients. When controlling for histological subtypes, however, ethnic variations in these mutations were no longer
significant. FBXW7 mutations (n=4, 40%, p=0.03) were found to occur
at a lower rate in non-Hispanic African American patients. No significant differences in the rates of genetic mutations were found
in Hispanic, Asian, or American Indian/Native Alaskan patients. 21
patients received targeted treatments based on sequencing results.
Among ethnic groups, 9.8% (n=17) of non-Hispanic Caucasian and
12.1% (n=4) of non-Hispanic African American patients were initiated
on targeted treatments (p=0.68). The majority of patients receiving
targeted therapy had endometrioid histology (n=11, 52.4%), followed
by carcinosarcoma (n=5, 23.8%) and serous (n=4, 19.0%) histology.
Conclusions: Genomic sequencing of solid tumors was utilized in a
high percentage of patients with endometrial cancer. When examining ethnic groups, no disparate use of tumor sequencing was
found. Similar actionable mutations were seen across ethnic groups
when controlling for tumor histology. Overall, utilization of tumor
sequencing results to personalize care was used at a low rate among
patients with actionable mutations across ethnic groups. This underutilization highlights the need for the continued development of efficacious, targeted therapies for endometrial cancer.

239 - Poster Session
Differentially expressed genes in platinum-resistant high-grade
serous ovarian cancer
Logan Corey, MD1, Ayesha Alvero, MD, MSc1, Nivedita Tiwari, M Sc2,
Yuan You1, Ramandeep Rattan, PhD2, Seongho Kim, PhD1, Gil Mor,
MD1, Radhika Gogoi, MD, PhD1
1
Wayne State University, Detroit, MI, United States, 2Henry Ford
Hospital, Detroit, MI, United States

Objectives: The purpose of this study was to identify genes and pathways differentially expressed in platinum resistant high grade serous
ovarian cancer (HGSOC) when compared to sensitive HGSOC.
Methods: A total of 37 patients with HGSOC tissue samples underwent RNA sequencing performed by TEMPUS (N=37, 21 platinum
sensitive, 16 resistant; 85% Stage III-IV; 58% received neoadjuvant
chemotherapy). RNA gene expression data and significantly impacted
pathways were analyzed using Advaita Bio’s iPathwayGuide.
Differentially expressed (DE) genes were identified using FDR of
0.05 and fold-change of 1.5. Genes from several impacted canonical
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metabolic pathways were validated by PCR against external data sets
in a separate ovarian cancer sample group (n=15), platinum resistant ovarian cancer mouse tumor model, and wild-type sensitive and
platinum resistant ovarian cancer cell lines. Relative gene expression
was calculated using the comparative Ct method, also referred to as
the “2 DDCT”, using L27 as internal control gene.
Results: We identified 177 differentially expressed (DE) genes out
of a total of 16,607 genes (1.1%) with measured expression. 15 pathways were found to be significantly impacted. Of the 15 canonical pathways, all were up regulated in the resistant HGSOC and
the majority of the most significantly altered (5/10) were related
to metabolism (Retinol metabolism (p-value = 0.002); Tyrosine
Metabolism (p-value = 0.005); Tryptophan Metabolism (p-value =
0.009); and Phenylalanine Metabolism (p-value = 0.012); CYP Drug
Metabolism (p-value = 0.022)). A total of 3 separate genes from the
CYP family and two from the Dopa Decarboxylase family of genes
were validated against an external data set of human ovarian tissue
samples, cell lines, mouse ovarian tumor model, and found to
have similarly increased gene expression in the genes tested in the
platinum resistant groups. Compilation of KEGG analysis and the
common network genes revealed pathways associated with amino
acid metabolism to be most significantly altered.
Conclusions: We describe the identification of a unique transcriptomic profile associated with platinum resistance. Interestingly, the
main pathways identified are related to metabolism, suggesting that
the survival to chemotherapy demands a major metabolic adaptation. These findings also represent a first step towards the identification of biomarkers for the detection of chemo-resistant disease and
metabolism-based drug targets specific for chemo-resistant tumors.
Further validation of this model is required in order to determine its
clinical value.
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240 - Poster Session
Differentiated vulvar intraepithelial neoplasia has a high-risk of
recurrence and progression to invasive vulvar cancer
Jill Roberts, MD1, Jessica Dillon, MD MS1, Ilana Cass, MD1
1
Dartmouth-Hitchcock Medical Center, Lebanon, NH, United States

Objectives: Differentiated vulvar intraepithelial neoplasia (dVIN) is
implicated as a precursor to HPV-negative squamous cell carcinoma
of the vulva (SCCV). It has a variable clinical course that has not yet
been fully characterized. Data on the clinical and histopathologic features of dVIN, risk of recurrence and progression to SCCV is limited.
Our objective was to describe the natural history of dVIN and evaluate predictors of recurrence and disease progression to carcinoma in
a cohort of women with histologically confirmed disease.
Methods: Under an IRB-approved protocol, we retrospectively
identified 27 patients with biopsy-proven dVIN from 2011 to 2020.
Cases were independently reviewed by 2 gynecologic pathologists.
Demographics, histopathologic features including immunohistochemical (IHC) staining for p16, p53, ER/PR and GATA 3 and clinical
course were abstracted. Patients were followed with semi-annual
exams and biopsies at the discretion of their gynecologic provider.
Results: Median age of the cohort was 70 years (range 43-91).
Median follow-up time was 4 months (range 1-21). All women were
Caucasian. The majority of women had concurrent lichen sclerosus
(LS) adjacent to dVIN (81%). No specific primary treatment (topical
versus surgical excision) was superior in preventing recurrence or
progression to SCCV. 67% of women had recurrent dVIN at a median
of 8 months from the initial diagnosis. 10 women had SCCV during
the study period: 4 (15%) at primary diagnosis adjacent to dVIN,
and 6 (22%) progressed to SCCV. Median time to progression was
34 months (range 1-120). P53 mutation (including p53 overexpression or p53 null) was associated with progression to SCCV (p<0.01).
Decreased GATA 3 staining was associated with both recurrence
(p=0.03) and progression to SCCV (p<0.01).
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